The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes: Copenhagen, Denmark Saturday, April 2 ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...

The management board of Nordecon AS (the " Company ”) (registry code 10099962, address Toompuiestee 35, 10149 Tallinn) hereby calls an annual general meeting of shareholders, which shall be held on 21 ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Zealand Pharma (ZLDPF) announces the appointment of Utpal Singh as Chief Scientific Officer. Utpal will join the executive team to lead ...

Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...